Recent evidence from our laboratory has demonstrated that a1-adrenoceptor antagonists doxazosin and terazosin induced apoptosis in prostate epithelial and smooth muscle cells in patients with benign prostatic hypertrophy (BPH; J. Urol., 159: 1810–1815, 1998; J. Urol., 161: 2002– 2007, 1999). In this study, we investigated the biological action of three a1-adrenoceptor antagonists, doxazosin, te...

Initially a dose-response curve of phenylephrine was constructed at dose strengths of 1-16 microg/kg in a cumulative manner. Phenylephrine caused a significant rise in the mean arterial pressure, left ventricular systolic pressure, left ventricular contractility, stroke volume and a significant decline in the heart rate. Terazosin was administered in three selected doses of 10, 100 and 300 micr...

The aim of this study was to compare the impacts of terazosin and tamsulosin, on prostate activity, i.e., serum prostate-specific antigen, total prostate volume (TPV), and transition zone volume (TZV). A total of 90 patients who presented with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), ranging in age from 52 to 83 yr (median 65 yr), were included in the...

OBJECTIVES To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH). METHODS This was a long-term (42 months), open-label, multicenter study with patients evaluated at 1- to 6-month intervals. Twenty-three outpatient clinics throughout the United States and Canada participated in the study. A total of 494 men w...

OBJECTIVE To evaluate the cost-effectiveness of tamsulosin, doxazosin, or terazosin as initial treatments for moderate benign prostatic hyperplasia (BPH) over a 3-year time horizon from a health-system-payer perspective. METHODS A decision-analytic model is used to project the course of treatment at 6-month intervals over 3 years following initiation of therapy with tamsulosin, doxazosin, or ...

Background: We evaluated the efficacy and tolerability of tamsulosin versus terazosin in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Methods: Patients (N = 1,993) were randomized to tamsulosin (0.4 mg/day) or terazosin (5 mg/day, following titration). The primary efficacy endpoint was total American Urological Association Symptom Index (AUA-SI) score after 4 days of ...

An efficient dispersive liquid-liquid microextraction using tetraalkylammonium bromide coated silver nanoparticles (DLLME-AgNPs) prepared in chloroform has been successfully applied as electrostatic affinity probes to the microextraction and preconcentration of terazosin prior to spectrofluorimetry analysis. This technique is based on a ternary system of solvents, where appropriate amount of mi...

PURPOSE We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and Internati...

Benign prostatic hyperplasia (BPH), common in aging males is often treated with alpha1-adrenoceptor (AR) antagonists. In view of known hypotensive effect of most of the alpha1-AR antagonists, this work examined the effect of a selected alpha1-AR antagonist, terazosin on the baroreceptor mediated regulation of blood pressure. The three doses of terazosin (10, 100, 300 microg/kg body weight) used...